drugset / Trial / NCT04874948
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Phase 1
Completed
4 enrolled
Michael Hoelscher
Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of \[14C\]BTZ-043 in 4 healthy adult male subjects
Timeline
- Start
- 2021-10-08
- Primary completion
- 2021-10-15
- Completion
- 2021-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BTZ-043 | Small molecule | 500 mg | Oral |